WO2006107903A3 - Polymeric micelles for drug delivery - Google Patents

Polymeric micelles for drug delivery Download PDF

Info

Publication number
WO2006107903A3
WO2006107903A3 PCT/US2006/012382 US2006012382W WO2006107903A3 WO 2006107903 A3 WO2006107903 A3 WO 2006107903A3 US 2006012382 W US2006012382 W US 2006012382W WO 2006107903 A3 WO2006107903 A3 WO 2006107903A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
polymeric micelles
micelles
polymeric
field
Prior art date
Application number
PCT/US2006/012382
Other languages
French (fr)
Other versions
WO2006107903A2 (en
Inventor
Kurt Breitenkamp
Kevin Sill
Habib Skaff
Rebecca Breintenkamp
Original Assignee
Intezyne Technologies Inc
Kurt Breitenkamp
Kevin Sill
Habib Skaff
Rebecca Breintenkamp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT06749187T priority Critical patent/ATE440117T1/en
Priority to JP2008504516A priority patent/JP4390845B2/en
Priority to MX2007012157A priority patent/MX2007012157A/en
Priority to AU2006231452A priority patent/AU2006231452B2/en
Priority to KR1020077024561A priority patent/KR101288729B1/en
Priority to DE602006008625T priority patent/DE602006008625D1/en
Application filed by Intezyne Technologies Inc, Kurt Breitenkamp, Kevin Sill, Habib Skaff, Rebecca Breintenkamp filed Critical Intezyne Technologies Inc
Priority to EP06749187A priority patent/EP1907444B1/en
Priority to CA2603853A priority patent/CA2603853C/en
Priority to NZ562064A priority patent/NZ562064A/en
Publication of WO2006107903A2 publication Critical patent/WO2006107903A2/en
Publication of WO2006107903A3 publication Critical patent/WO2006107903A3/en
Priority to IL186254A priority patent/IL186254A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.
PCT/US2006/012382 2005-04-01 2006-04-03 Polymeric micelles for drug delivery WO2006107903A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2008504516A JP4390845B2 (en) 2005-04-01 2006-04-03 Polymer micelles for drug delivery
MX2007012157A MX2007012157A (en) 2005-04-01 2006-04-03 Polymeric micelles for drug delivery.
AU2006231452A AU2006231452B2 (en) 2005-04-01 2006-04-03 Polymeric micelles for drug delivery
KR1020077024561A KR101288729B1 (en) 2005-04-01 2006-04-03 Polymeric micelles for drug delivery
DE602006008625T DE602006008625D1 (en) 2005-04-01 2006-04-03 POLYMERMICELLES FOR DRUG DELIVERY
AT06749187T ATE440117T1 (en) 2005-04-01 2006-04-03 POLYMER MICELLES FOR MEDICINAL DELIVERY
EP06749187A EP1907444B1 (en) 2005-04-01 2006-04-03 Polymeric micelles for drug delivery
CA2603853A CA2603853C (en) 2005-04-01 2006-04-03 Polymeric micelles for drug delivery
NZ562064A NZ562064A (en) 2005-04-01 2006-04-03 Polymeric micelles for drug delivery
IL186254A IL186254A (en) 2005-04-01 2007-09-25 Polymeric micelles for drug delivery

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66726005P 2005-04-01 2005-04-01
US60/667,260 2005-04-01
US74178005P 2005-12-01 2005-12-01
US60/741,780 2005-12-01

Publications (2)

Publication Number Publication Date
WO2006107903A2 WO2006107903A2 (en) 2006-10-12
WO2006107903A3 true WO2006107903A3 (en) 2007-02-15

Family

ID=36951510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/012382 WO2006107903A2 (en) 2005-04-01 2006-04-03 Polymeric micelles for drug delivery

Country Status (13)

Country Link
US (6) US7638558B2 (en)
EP (1) EP1907444B1 (en)
JP (1) JP4390845B2 (en)
KR (1) KR101288729B1 (en)
AT (1) ATE440117T1 (en)
AU (1) AU2006231452B2 (en)
CA (1) CA2603853C (en)
DE (1) DE602006008625D1 (en)
ES (1) ES2332062T3 (en)
IL (1) IL186254A (en)
MX (1) MX2007012157A (en)
NZ (1) NZ562064A (en)
WO (1) WO2006107903A2 (en)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080281041A1 (en) 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US8138383B2 (en) * 2002-03-11 2012-03-20 Arrowhead Madison Inc. Membrane active heteropolymers
US8008355B2 (en) * 2002-03-11 2011-08-30 Roche Madison Inc. Endosomolytic poly(vinyl ether) polymers
US20040005351A1 (en) * 2002-03-29 2004-01-08 Kwon Glen S. Polymeric micelle formulations of hydrophobic compounds and methods
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
AU2004273986B2 (en) 2003-09-15 2010-04-22 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use in angiogenesis
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
EP1732485A2 (en) * 2004-01-02 2006-12-20 Wisconsin Alumni Research Foundation Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
MX2007008195A (en) 2005-01-04 2008-02-22 Intezyne Technologies Llc Synthesis of hybrid block copolymers and uses thereof.
US9220788B2 (en) 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US20100209382A1 (en) 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
WO2007127440A2 (en) 2006-04-27 2007-11-08 Intezyne Technologies, Inc. Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
WO2007127473A2 (en) 2006-04-27 2007-11-08 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
US20080035667A1 (en) * 2006-06-07 2008-02-14 Osg Norwich Pharmaceuticals, Inc. Liquid delivery system
US20100015068A1 (en) * 2006-07-06 2010-01-21 Massachusetts Institute Of Technology Methods and Compositions For Altering Biological Surfaces
US8066824B2 (en) * 2006-07-07 2011-11-29 Intezyne Technologies, Inc. Covalent modification of metal surfaces
CN102614528B (en) * 2006-08-18 2014-02-26 箭头研究公司 Polyconjugates for in vivo delivery of polynucleotides
WO2008070284A2 (en) 2006-10-16 2008-06-12 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute Amyloid beta peptides and methods of uses thereof
US8414927B2 (en) * 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
JP5569899B2 (en) * 2006-11-28 2014-08-13 ウィスコンシン・アラムナイ・リサーチ・ファウンデーション Fluoropolymer-based emulsion for intravenous delivery of volatile fluorinated anesthetics
EP2101734B1 (en) * 2006-12-01 2013-01-23 The Regents of the University of California Vesicles of self-assembling block copolymers and methods for making and using the same
WO2008070141A2 (en) * 2006-12-06 2008-06-12 Wisconsin Alumni Research Foundation Compositions for delivery of therapeutic agents
CA2673133C (en) * 2006-12-22 2016-08-30 Clf Medical Technology Acceleration Program, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20100297023A1 (en) * 2006-12-22 2010-11-25 Imuthes Limited University Of The Witwatersrand Lipid
US8900562B2 (en) * 2007-01-12 2014-12-02 Wisconsin Alumni Research Foundation Semi-fluorinated block copolymers for delivery of therapeutic agents
WO2008089487A2 (en) * 2007-01-19 2008-07-24 The Cleveland Clinic Foundation Carboxyethylpyrrole compounds and methods of their production
WO2008089485A2 (en) * 2007-01-19 2008-07-24 The Cleveland Clinic Foundation Carboxyethylpyrrole compounds and methods of their production
US7758635B2 (en) * 2007-02-13 2010-07-20 Boston Scientific Scimed, Inc. Medical device including cylindrical micelles
JP2010519305A (en) * 2007-02-26 2010-06-03 ウィスコンシン・アルムニ・リサーチ・ファウンデーション Polymeric micelles for combined drug delivery
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
EP2152320A2 (en) * 2007-04-30 2010-02-17 Intezyne Technologies Incorporated Encapsulated contrast agents
ES2432641T3 (en) * 2007-04-30 2013-12-04 Intezyne Technologies Inc. Hybrid micelles of block copolymer with mixed stereochemistry for encapsulation of hydrophobic agents
WO2008144475A1 (en) 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
JP2011503067A (en) * 2007-11-07 2011-01-27 マリンクロッド・インコーポレイテッド Crosslinked and functionalized nanostructures with photonic shell cores for biological applications
US20110104052A1 (en) * 2007-12-03 2011-05-05 The Johns Hopkins University Methods of synthesis and use of chemospheres
JP2011511674A (en) 2008-02-07 2011-04-14 ユニヴァーシティ オブ ワシントン Circumferential aerosol device
US20090232762A1 (en) * 2008-03-11 2009-09-17 May Pang Xiong Compositions for delivery of therapeutic agents
US8034396B2 (en) 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
JP5317031B2 (en) * 2008-05-07 2013-10-16 公立大学法人大阪府立大学 Hollow nano-particles of head-tail copolymer
GB2460672B (en) * 2008-06-04 2012-01-04 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
PL2281576T3 (en) * 2008-07-29 2013-12-31 Nanocarrier Co Ltd Active targeting type polymeric micelle carrying drug enclosed therein and medicinal composition
WO2010036961A1 (en) * 2008-09-25 2010-04-01 Invivo Therapeutics Corporation Spinal cord injury, inflammation, and immune-disease: local controlled release of therapeutic agents
WO2010036973A1 (en) * 2008-09-25 2010-04-01 Comgenrx, Inc. Treatment of hyperproliferative disorders using cardiac glycosides
US9173840B2 (en) * 2008-10-09 2015-11-03 Northeastern University Multifunctional self-assembling polymeric nanosystems
KR20110095292A (en) * 2008-11-06 2011-08-24 유니버시티 오브 워싱톤 Multiblock copolymers
AU2013204152B2 (en) * 2008-11-06 2016-04-14 Phaserx, Inc. Multiblock copolymers
WO2010075332A1 (en) * 2008-12-23 2010-07-01 Charitable Leadership Foundation Small molecule ligands of the integrin rgd recognition site and methods of use
US9523159B2 (en) 2009-02-21 2016-12-20 Covidien Lp Crosslinked fibers and method of making same using UV radiation
AU2010215203B2 (en) 2009-02-21 2015-07-16 Covidien Lp Medical devices with an activated coating
US8663689B2 (en) 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
WO2010095045A1 (en) 2009-02-21 2010-08-26 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
WO2010095052A2 (en) * 2009-02-21 2010-08-26 Sofradim Production Compounds and medical devices activated with solvophobic linkers
US8968733B2 (en) 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
CA2753166A1 (en) 2009-02-21 2010-08-26 Sofradim Production Apparatus and method of reacting polymers by exposure to uv radiation to produce injectable medical devices
AU2010215196B2 (en) 2009-02-21 2015-04-16 Covidien Lp Crosslinked fibers and method of making same by extrusion
CA2753188A1 (en) 2009-02-21 2010-08-26 Tyco Healthcare Group Lp Medical devices having activated surfaces
WO2010095047A2 (en) 2009-02-21 2010-08-26 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
EP2398524B1 (en) 2009-02-21 2017-07-12 Covidien LP Medical devices having activated surfaces
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US8877170B2 (en) 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
WO2010127159A2 (en) * 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
WO2010127154A1 (en) * 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymers for polynucleotide encapsulation
US8524784B2 (en) 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
US8524783B2 (en) * 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
EP2427176A4 (en) * 2009-05-04 2014-03-19 Intezyne Technologies Inc Polymer micelles containing sn-38 for the treatment of cancer
US8236329B2 (en) * 2009-09-25 2012-08-07 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
US9415113B2 (en) 2009-11-18 2016-08-16 University Of Washington Targeting monomers and polymers having targeting blocks
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
WO2011102905A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion diagnostic delivery system
WO2011102906A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion delivery system
EP3023495B1 (en) * 2010-02-24 2019-05-08 Arrowhead Pharmaceuticals, Inc. Compositions for targeted delivery of sirna
US20110229528A1 (en) * 2010-03-12 2011-09-22 Intezyne Technologies, Incorporated Pegylated polyplexes for polynucleotide delivery
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
US9272074B2 (en) 2010-03-25 2016-03-01 Sofradim Production Surgical fasteners and methods for sealing wounds
US8795331B2 (en) 2010-03-25 2014-08-05 Covidien Lp Medical devices incorporating functional adhesives
FR2958649B1 (en) * 2010-04-07 2012-05-04 Arkema France BLOCK COPOLYMER FROM RENEWABLE MATERIALS AND PROCESS FOR PRODUCING SUCH A BLOCK COPOLYMER
WO2011143524A2 (en) * 2010-05-14 2011-11-17 Mallinckrodt Llc Functional, cross-linked nanostructures for tandem optical imaging and therapy
WO2012006147A1 (en) 2010-06-29 2012-01-12 Tyco Healthcare Group Lp Microwave-powered reactor and method for in situ forming implants
AU2011273102A1 (en) 2010-07-01 2013-01-31 Sofradim Production Medical device with predefined activated cellular integration
WO2012018594A2 (en) * 2010-07-26 2012-02-09 Scott & White Healthcare Plant-derived polysaccharides for delivery of rna-based therapies
WO2012014080A2 (en) 2010-07-27 2012-02-02 Sofradim Production Polymeric fibers having tissue reactive members
PT2608800T (en) 2010-08-23 2017-05-03 Amicrobe Inc Compositions and uses of materials with high antimicrobial activity and low toxicity
US11344505B1 (en) 2010-12-01 2022-05-31 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US11414663B2 (en) 2010-12-01 2022-08-16 Gowey Research Group, Pllc Micro-RNA profiling, compositions, and methods of treating diseases
US10758578B2 (en) 2010-12-01 2020-09-01 Gowey Research Group PLLC Herbal formulations of carnivorous plants and methods for treating inflammation
US10744151B1 (en) * 2010-12-01 2020-08-18 Gowey Research Group PLLC Micro-RNA profiling, compositions, and methods of treating diseases
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
BR112013022249B8 (en) 2011-03-03 2022-10-25 Impel Neuropharma Inc NASAL DRUG DISTRIBUTION DEVICE
US9498533B2 (en) 2011-04-04 2016-11-22 Board Of Regents Of The University Of Nebraska Drug delivery compositions and methods
WO2012140674A1 (en) 2011-04-11 2012-10-18 Council Of Scientific & Industrial Research Surface induced disassembly of nano containers
CN107376071B (en) 2011-05-09 2021-07-09 英倍尔药业股份有限公司 Nozzle for delivering a compound to the upper olfactory region of a user
EP2714023A4 (en) * 2011-05-23 2014-12-24 Univ Massachusetts Crosslinked polymer nano-assemblies and uses thereof
EP2543685A1 (en) * 2011-07-08 2013-01-09 cynora GmbH Method for covalent binding of a metal compound to a polymer
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US8609146B2 (en) 2011-09-19 2013-12-17 Intezyne Technologies, Inc. Multi-block copolymers for the preparation of stabilized micelles
KR101334420B1 (en) * 2011-11-17 2013-11-29 재단법인대구경북과학기술원 Core cross-linked polymeric micelle for drug delivery and method of manufacturing the same
TWI568453B (en) * 2011-11-22 2017-02-01 原創生醫股份有限公司 A drug carrier with chelating complex micelles and the application thereof
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2013124867A1 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
ES2531054T3 (en) * 2012-02-29 2015-03-10 Enzypep B V Condensation of protected side chain oligopeptide fragment by using subtilisins in organic solvents
CN108949772A (en) 2012-04-02 2018-12-07 现代泰克斯公司 For generating the modification polynucleotides of biological agent relevant to human diseases and protein
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc Modified polynucleotides for the production of proteins
AU2013201541B2 (en) * 2012-04-11 2014-08-14 Intezyne Technologies, Inc. Block copolymers for stable micelles
US20140113879A1 (en) * 2012-04-11 2014-04-24 Intezyne Technologies, Inc. Block copolymers for stable micelles
US20140127271A1 (en) * 2012-04-11 2014-05-08 Intezyne Technologies, Inc. Block copolymers for stable micelles
US9944752B2 (en) 2012-04-11 2018-04-17 Intezyne Technologies, Inc. Block copolymers for stable micelles
US9597406B2 (en) * 2012-08-28 2017-03-21 Original BioMedicals Co., Ltd Controlled release method for a pharmaceutical composition composed of chelating complex micelles
US20140134601A1 (en) * 2012-11-09 2014-05-15 Korea University Research And Business Foundation Use of protein nanoparticle based hydrogel
KR101403191B1 (en) * 2012-11-19 2014-06-02 가톨릭대학교 산학협력단 Janus and Multimeric Micelle for Drug Delivery, and Method for Preparing the Same
WO2014141289A1 (en) 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
WO2014168986A1 (en) 2013-04-08 2014-10-16 Brown Dennis M Therapeutic benefit of suboptimally administered chemical compounds
JP2016520378A (en) 2013-04-28 2016-07-14 インペル ニューロファーマ インコーポレイテッド Medical unit dose container
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
JP2016530294A (en) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Chimeric polynucleotide
FR3011550B1 (en) * 2013-10-07 2016-11-18 Arkema France POLYAMIDE BLOCK COPOLYMER AND POLYETHER BLOCK
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
WO2015074050A1 (en) 2013-11-18 2015-05-21 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
SI3071696T1 (en) 2013-11-22 2019-11-29 Mina Therapeutics Ltd C/ebp alpha short activating rna compositions and methods of use
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US9622970B2 (en) * 2014-05-08 2017-04-18 Yaguang Liu Pharmaceutical composition containing lutein and antioxidant for treating and preventing human disease
WO2015179402A1 (en) 2014-05-19 2015-11-26 North Carolina State University Methods of folding a graft copolymer with dual anticancer drugs and related applications
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
EP3191131A4 (en) 2014-08-21 2018-09-05 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
WO2016054432A1 (en) 2014-10-01 2016-04-07 The Regents Of The University Of California Non-ionic and thermoresponsive diblock copolypeptide hydrogels for delivery of molecules and cells
CN104448300B (en) * 2014-12-09 2017-01-11 西安医学院 Low-molecular-weight L-polyglutamine-mitomycin C as well as synthesis method and applications thereof
US11633355B2 (en) 2014-12-12 2023-04-25 Clemson University Research Foundation Multi-functional particles and methods of using the same
US10232050B1 (en) 2014-12-12 2019-03-19 Clemson University Multi-functional particles and methods of using the same
US9956300B2 (en) * 2015-03-18 2018-05-01 Duke Univerity Hydrogels formed from polypeptide micelles and methods of use thereof
FR3034423B1 (en) * 2015-04-03 2019-05-31 Cnrs AQUEOUS DISPERSION OF PARTICLES OF AT LEAST ONE THERMOPLASTIC POLYMER, PROCESS FOR PREPARING THE SAME AND APPLICATIONS THEREOF, IN PARTICULAR FOR THE SINGING OF REINFORCING FIBERS
WO2016187264A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Enhanced melanoma cancer prevention by novel melanotropins
EP3302579A4 (en) * 2015-05-26 2019-01-02 Intezyne Technologies Inc. Iron stabilized micelles as magnetic contrast agents
WO2017044897A1 (en) 2015-09-10 2017-03-16 Impel Neuropharma Inc. In-line nasal delivery device
KR20180096592A (en) 2015-10-22 2018-08-29 모더나티엑스, 인크. Respiratory syncytial virus vaccine
CN117731769A (en) 2015-10-22 2024-03-22 摩登纳特斯有限公司 Nucleic acid vaccine for Varicella Zoster Virus (VZV)
TN2018000155A1 (en) 2015-10-22 2019-10-04 Modernatx Inc Herpes simplex virus vaccine
JP6921833B2 (en) 2015-10-22 2021-08-18 モデルナティーエックス， インコーポレイテッド Human cytomegalovirus vaccine
EP4349404A2 (en) 2015-10-22 2024-04-10 ModernaTX, Inc. Respiratory virus vaccines
BR112018008078A2 (en) 2015-10-22 2018-11-13 Modernatx Inc broad spectrum influenza virus vaccine
PT3394093T (en) 2015-12-23 2022-05-30 Modernatx Inc Methods of using ox40 ligand encoding polynucleotides
MA43587A (en) 2016-01-10 2018-11-14 Modernatx Inc THERAPEUTIC RNA CODING FOR ANTI-CTLA-4 ANTIBODIES
KR101905010B1 (en) 2016-04-19 2018-10-08 앱티스 주식회사 A composition for solubilizing coenzyme Q10 and method for preparing the same
AU2017279536A1 (en) 2016-06-07 2018-12-20 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αvβ3 integrin thyroid antagonists
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
WO2018148432A1 (en) 2017-02-08 2018-08-16 Intezyne Technologies, Inc. Sn-38 loaded iron crosslinked micelle and methods thereof
CN110591078B (en) * 2017-06-26 2021-11-05 苏州大学 Preparation method of reduction/pH dual-responsiveness adriamycin prodrug
WO2019048645A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
CA3075219A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Hnf4a sarna compositions and methods of use
WO2019094702A1 (en) 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
JP2021503988A (en) 2017-11-21 2021-02-15 インペル ニューロファーマ インコーポレイテッド Intranasal device with inlet interface
US11571532B2 (en) 2017-11-21 2023-02-07 Impel Pharmaceuticals Inc. Intranasal device with dip tube
WO2019113461A1 (en) * 2017-12-08 2019-06-13 Western University Of Health Sciences Lipid emulsified drug delivery systems for chemoprevention and treatment
WO2019129657A1 (en) 2017-12-28 2019-07-04 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Actively targeted polymeric micelles for drug and gene delivery
US20190209463A1 (en) 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of dihydroergotamine by precision olfactory device
KR20200118034A (en) 2018-01-05 2020-10-14 임펠 뉴로파마 인코포레이티드 Intranasal delivery of olanzapine by a precision olfactory organ device
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
EP4242307A3 (en) 2018-04-12 2023-12-27 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
CN109111582A (en) * 2018-06-14 2019-01-01 哈尔滨工业大学无锡新材料研究院 A kind of polyetheramine-glutaric acid copolymer micelle and preparation method thereof
WO2020018959A1 (en) 2018-07-19 2020-01-23 Impel Neuropharma, Inc. Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
SG11202107019VA (en) 2019-01-03 2021-07-29 Impel Neuropharma Inc Nasal drug delivery device
WO2020208361A1 (en) 2019-04-12 2020-10-15 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
CA3140374A1 (en) 2019-05-17 2020-11-26 Impel Neuropharma, Inc. Single-use nasal delivery device
CN112999151B (en) * 2019-12-19 2024-03-19 鲁南制药集团股份有限公司 Paclitaxel composite micelle for oral administration
KR102376945B1 (en) * 2019-12-19 2022-03-21 상지대학교산학협력단 Parkinson's disease pharmaceutical composition and its therapeutic agent
CN113024789B (en) * 2019-12-23 2023-01-06 福建省紫杉园药业有限责任公司 Crosslinked polymer micelle and preparation method and application thereof
CN111228301A (en) * 2020-01-14 2020-06-05 哈尔滨医科大学 Compound preparation for treating angiogenesis-mediated diseases and preparation method and application thereof
CN111297876B (en) * 2020-01-16 2021-04-27 武汉理工大学 Celecoxib micelle and honokiol micelle drug combination controlled release system and preparation method thereof
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
JP2024501974A (en) * 2020-12-28 2024-01-17 公益財団法人川崎市産業振興財団 Polyion complex micelles
KR20230160872A (en) 2021-03-26 2023-11-24 미나 테라퓨틱스 리미티드 TMEM173 SARNA composition and methods of use
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
CN114957733B (en) * 2022-05-12 2024-04-05 安徽工程大学 Boc-phenylalanine modified starch nano-particles, preparation method thereof and application thereof in hydrophobic drug loading
CN114920869B (en) * 2022-05-24 2023-07-14 太原工业学院 Amphiphilic arginine block ciprofloxacin copolymer, nanoparticle, preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1230934A1 (en) * 1999-11-19 2002-08-14 NanoCarrier Co., Ltd. Polyion complex micelles of core/shell structure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2240547A (en) 1990-01-31 1991-08-07 Ciba Geigy Ag New compositions
KR940003548U (en) * 1992-08-14 1994-02-21 김형술 Laundry dryer
BR9610120A (en) * 1995-09-07 1999-12-21 Univ Georgia Res Found Pharmaceutical composition and process to increase the half-life of a drug in an individual and to improve a pathological condition in a patient.
JPH11335267A (en) 1998-05-27 1999-12-07 Nano Career Kk Polymer micelles including water soluble medicine
JP3523821B2 (en) * 2000-02-09 2004-04-26 ナノキャリア株式会社 Method for producing polymer micelle in which drug is encapsulated and polymer micelle composition
FR2814951B1 (en) * 2000-10-06 2003-01-17 Flamel Tech Sa COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR VECTORIZATION OF ACTIVE HYDROPHILIC PRINCIPLES (INSULIN) AND THEIR METHOD OF PREPARATION
FR2822834B1 (en) * 2001-04-02 2005-02-25 Flamel Tech Sa COLLOIDAL SUSPENSION OF NANOPARTICLES BASED ON AMPHIPHILIC COPOLYMERS FOR VECTORIZATION OF ACTIVE INGREDIENTS AND THEIR METHOD OF PREPARATION
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
US20050249786A1 (en) 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
JP2004010479A (en) * 2002-06-03 2004-01-15 Japan Science & Technology Corp New solid pharmaceutical preparation comprising block copolymer and anthracycline anticancer agent, and method for producing the same
JP2004018494A (en) * 2002-06-19 2004-01-22 Japan Science & Technology Corp Method for producing block copolymer-medicine composite material
JP4535229B2 (en) * 2003-05-08 2010-09-01 国立大学法人 東京大学 Polyethylene glycol-polycation block copolymer
JP4763459B2 (en) 2003-05-29 2011-08-31 株式会社東京大学Ｔｌｏ Stabilized polymer micelle
JP2006199590A (en) 2003-09-04 2006-08-03 Nano Career Kk Composition containing nanoparticle containing water-soluble basic medicine encapsulated therein
US7311901B2 (en) * 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
CA2584510C (en) * 2004-10-25 2013-05-28 Intezyne Technologies, Incorporated Heterobifunctional poly(ethylene glycol) and uses thereof
IL165260A0 (en) 2004-11-16 2005-12-18 Yissum Res Dev Co Polymeric nano-shells
MX2007008195A (en) * 2005-01-04 2008-02-22 Intezyne Technologies Llc Synthesis of hybrid block copolymers and uses thereof.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1230934A1 (en) * 1999-11-19 2002-08-14 NanoCarrier Co., Ltd. Polyion complex micelles of core/shell structure

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE COMPENDEX [online] ENGINEERING INFORMATION, INC., NEW YORK, NY, US; NISHIYAMA NOBUHIRO ET AL: "Preparation and characterization of self-assembled polymer-metal complex micelle from cis-dichlorodiammineplatinum(II) and poly(ethylene glycol)-poly(alpha ,beta -aspartic acid) block copolymer in an aqueous medium", XP002400377, Database accession no. EIX99154568522 *
LANGMUIR; LANGMUIR JAN 19 1999 ACS, WASHINGTON, DC, USA, vol. 15, no. 2, 19 January 1999 (1999-01-19), pages 377 - 383 *
Y. KAKIZAWA: "Environment-sensitive stabilization of core-shell structured polyion complex micelle by reversible cross-linking of the core through disulfide bond", J. AM. CHEM. SOC., vol. 121, 1999, pages 11247 - 11248, XP002398895 *
Y. KAKIZAWA: "Glutathione-sensitive stabilization of block copolymer micelles composed of antisense DNA and thiolated poly(ethylene glycol)-block-poly(L-lysine): A potential carrier for systemic delivery of antisense DNA", BIOMACROMOLECULES, vol. 2, 2001, pages 491 - 497, XP002398894 *

Also Published As

Publication number Publication date
KR101288729B1 (en) 2013-07-23
US20130195987A1 (en) 2013-08-01
US8263665B2 (en) 2012-09-11
CA2603853A1 (en) 2006-10-12
US20100159020A1 (en) 2010-06-24
US20060240092A1 (en) 2006-10-26
IL186254A0 (en) 2008-01-20
EP1907444B1 (en) 2009-08-19
US8299128B2 (en) 2012-10-30
ES2332062T3 (en) 2010-01-25
US20110092668A1 (en) 2011-04-21
NZ562064A (en) 2011-03-31
KR20080015070A (en) 2008-02-18
MX2007012157A (en) 2008-03-14
CA2603853C (en) 2013-11-19
EP1907444A2 (en) 2008-04-09
US8263663B2 (en) 2012-09-11
DE602006008625D1 (en) 2009-10-01
US8426477B1 (en) 2013-04-23
US8779008B2 (en) 2014-07-15
IL186254A (en) 2012-04-30
AU2006231452A1 (en) 2006-10-12
US20110091534A1 (en) 2011-04-21
JP4390845B2 (en) 2009-12-24
AU2006231452B2 (en) 2011-05-26
WO2006107903A2 (en) 2006-10-12
JP2008537943A (en) 2008-10-02
ATE440117T1 (en) 2009-09-15
US7638558B2 (en) 2009-12-29

Similar Documents

Publication Publication Date Title
WO2006107903A3 (en) Polymeric micelles for drug delivery
WO2006074202A3 (en) Synthesis of hybrid block copolymers and uses thereof
WO2007143159A3 (en) Medical devices having improved performance
WO2009141823A3 (en) Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
WO2009094361A3 (en) Conjugated polymers from substituted 3,4-propylenedioxythiophene, compositions, method of making, and use thereof
WO2008005371A3 (en) Poly(orthoester) polymers, and methods of making and using same
WO2007117556A3 (en) Pharmaceutical compositions and uses thereof
IL229304A (en) 1',3'-disubstituted- 4- phenyl- 3, 4, 5, 6 -tetrahydro-2h, 1'h - [1, 4'] bipyridinyl- 2'-ones, pharmaceutical compositions comprising them and uses thereof
WO2007147010A3 (en) Implantable medical devices and methods for making the same
WO2007109604A3 (en) Pharmaceutical compositions
IL201839A0 (en) Hybrid block copolymer micelles and methods of producing the same
WO2007010034A3 (en) Ampholytic copolymer, production thereof, and use of the same
WO2008094834A3 (en) Multi-functional drug carriers
WO2008121767A3 (en) Stitched polypeptides
WO2008034013A3 (en) Medical devices and methods of making the same
WO2006110776A3 (en) Polyethylene glycol cojugates of antimicrobial agents
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2008067145A3 (en) Self-assembling peptide amphiphiles
EP1922019A4 (en) Tri-block copolymers for nanosphere-based drug delivery
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
WO2012040623A3 (en) Nanostructured gels capable of controlled release of encapsulated agents
WO2007081991A3 (en) Novel conjugated materials featuring proquinoidal units
WO2008121508A3 (en) Implantable medical devices fabricated from block copolymers
HK1090936A1 (en) Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
EP2535058A3 (en) Stabilization of vaccines by lyophilization

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 186254

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2603853

Country of ref document: CA

Ref document number: 2008504516

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006231452

Country of ref document: AU

Ref document number: 562064

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/012157

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3753/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006749187

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006231452

Country of ref document: AU

Date of ref document: 20060403

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077024561

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU